Adven Biotech says it's India's first homeopathic brand to get NABL certification

Adven Biotech achieves a significant milestone as India's first homeopathy brand to earn NABL certification. This accreditation underscores India's commitment to global healthcare standards in the Ayush sector. The certification validates Adven's quality control and testing laboratories, aligning with Prime Minister Modi's vision for Ayush. It aims to boost confidence and expand the global acceptance of Indian homeopathy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zTj9iAE
via IFTTT

Read More

GST rejig marks key shift towards making cancer care affordable, AIIMS researchers says

AIIMS researchers highlight recent GST reforms, including tax exemptions on cancer drugs and medical equipment, aiming to make cancer care more affordable. Increased taxation on tobacco products is also noted as a positive step for public health and revenue generation for cancer initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7EB8Ql
via IFTTT

Read More

India becoming backbone of global clinical research

India has emerged as a key player in international clinical trials, showcasing resilience even in the face of global hurdles. With research and innovation on the rise, firms like Parexel recognize India's crucial contribution to ensuring consistent business operations. Instead of threats, artificial intelligence presents avenues for professionals to expand their roles and skillsets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZivtCy1
via IFTTT

Read More

Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Switzerland's Occlutech Holding. This strategic move aims to access high-value global markets. The deal is expected to finalize by June 2026. Occlutech is a key player in Europe's minimally invasive cardiac implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QRcUVtm
via IFTTT

Read More

AIIMS Delhi first in country to announce launch of face transplant programme

AIIMS New Delhi has become the first hospital in India to introduce face transplantation, a complex reconstructive procedure for patients with severe facial deformities. The Department of Plastic, Reconstructive and Burns Surgery has begun creating a patient registry and is conducting specialised training, including a cadaveric workshop, with support from international expert Dr Indranil Sinha of Harvard Medical School.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zHdnsOB
via IFTTT

Read More

HUL turns ₹70 cr bet in Wellbeing Nutrition into ₹307 cr exit

Hindustan Unilever has divested its 19.8% stake in Wellbeing Nutrition to UVS Pharma for Rs 307 crore. This move comes after HUL's initial Rs 70 crore investment in 2022. The transaction, expected to conclude by March 2026, sees Wellbeing Nutrition valued at approximately Rs 1,600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r7hxTCY
via IFTTT

Read More

Zydus settles US Mirabegron patent dispute with Astellas for $120 million

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2lCe6r
via IFTTT

Read More